Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 1
2010 2
2011 5
2012 10
2013 11
2014 12
2015 16
2016 17
2017 16
2018 11
2019 14
2020 19
2021 36
2022 53
2023 51
2024 49
2025 64
2026 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean belimumabs lupus nephritis (11 results)?
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Furie R, et al. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. N Engl J Med. 2020. PMID: 32937045 Clinical Trial.
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. ...The safety profile of bel …
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with pl …
Systemic Lupus Erythematosus: A Review.
Siegel CH, Sammaritano LR. Siegel CH, et al. JAMA. 2024 May 7;331(17):1480-1491. doi: 10.1001/jama.2024.2315. JAMA. 2024. PMID: 38587826 Review.
Approximately 40% of people with SLE develop lupus nephritis, and an estimated 10% of people with lupus nephritis develop end-stage kidney disease after 10 years. ...Three SLE medications were recently approved by the Food and Drug Administration: b …
Approximately 40% of people with SLE develop lupus nephritis, and an estimated 10% of people with lupus nephritis …
Lupus Nephritis from Pathogenesis to New Therapies: An Update.
Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, Francese A, Maconi AG, Quaglia M. Roveta A, et al. Int J Mol Sci. 2024 Aug 18;25(16):8981. doi: 10.3390/ijms25168981. Int J Mol Sci. 2024. PMID: 39201667 Free PMC article. Review.
Lupus Nephritis (LN) still represents one of the most severe complications of Systemic Lupus Erythematosus (SLE) and a major risk factor for morbidity and mortality. ...This review aims to provide a comprehensive update on progress on several key aspects in t …
Lupus Nephritis (LN) still represents one of the most severe complications of Systemic Lupus Erythematosus (SLE) and a …
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA. Furie R, et al. Clin J Am Soc Nephrol. 2022 Nov;17(11):1620-1630. doi: 10.2215/CJN.02520322. Epub 2022 Oct 27. Clin J Am Soc Nephrol. 2022. PMID: 36302567 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab's safety and efficacy. ...The seeming decrease in respo …
BACKGROUND AND OBJECTIVES: In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus ne …
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA. Rovin BH, et al. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560137 Free article. Clinical Trial.
Belimumab significantly reduced the risk of kidney-related events or death and lupus nephritis flare in the overall population. ...Thus, our data suggest that the addition of belimumab to standard therapy could attenuate the risk of lupus nep …
Belimumab significantly reduced the risk of kidney-related events or death and lupus nephritis flare in the overall pop …
Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis.
Shrestha S, Budhathoki P, Adhikari Y, Marasini A, Bhandari S, Mir WAY, Shrestha DB. Shrestha S, et al. Cureus. 2021 Dec 15;13(12):e20440. doi: 10.7759/cureus.20440. eCollection 2021 Dec. Cureus. 2021. PMID: 35047277 Free PMC article. Review.
We aimed to evaluate the role of belimumab in the maintenance phase of treatment for lupus nephritis (LN). PubMed, PubMed Central (PMC), Cochrane Library, and Embase were searched using appropriate keywords. ...Similarly, there was 34% lower odds for having n …
We aimed to evaluate the role of belimumab in the maintenance phase of treatment for lupus nephritis (LN). PubMed, PubM …
Lupus Nephritis in Children: Novel Perspectives.
Pennesi M, Benvenuto S. Pennesi M, et al. Medicina (Kaunas). 2023 Oct 16;59(10):1841. doi: 10.3390/medicina59101841. Medicina (Kaunas). 2023. PMID: 37893559 Free PMC article. Review.
Kidney involvement, commonly called lupus nephritis, mainly presents with immune complex-mediated glomerulonephritis and is more frequent and severe in adults. ...This review aims to describe pediatric lupus nephritis and provide an overview of the nov …
Kidney involvement, commonly called lupus nephritis, mainly presents with immune complex-mediated glomerulonephritis and is mo …
Systemic lupus erythematosus.
Hoi A, Igel T, Mok CC, Arnaud L. Hoi A, et al. Lancet. 2024 May 25;403(10441):2326-2338. doi: 10.1016/S0140-6736(24)00398-2. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642569 Review.
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterised by the presence of autoantibodies towards nuclear antigens, immune complex deposition, and chronic inflammation at classic target organs such as skin, joints, and kidneys. ...In the last …
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterised by the presence of autoantibodies towards nucl …
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694 Free article.
HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. ...CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active …
HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for f …
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis.
Chen Y, Shi N, Lei X, Ren P, Lan L, Chen L, Wang Y, Xu Y, Lin Y, Chen J, Han F. Chen Y, et al. Rheumatology (Oxford). 2025 Jan 1;64(1):221-227. doi: 10.1093/rheumatology/kead674. Rheumatology (Oxford). 2025. PMID: 38145455 Free article.
OBJECTIVE: Lupus nephritis is a severe and common complication of systemic lupus erythematosus (SLE). The pathogenesis of lupus nephritis is characterized by B-cell activation and autoantibody formation. Rituximab and belimumab, as well a …
OBJECTIVE: Lupus nephritis is a severe and common complication of systemic lupus erythematosus (SLE). The pathogenesis …
384 results